Chemours Company (CC) is currently showing signs of potential oversold conditions based on technical indicators. The Relative Strength Index (RSI) is at 31.80, indicating that the stock may be undervalued and due for a rebound. The MACD is currently negative (-1.18), suggesting bearish momentum, but the MACD histogram is showing early signs of a potential reversal.
Recent news indicates mixed sentiment among analysts. Barclays maintained a Hold rating with a price target of $19.00, while Truist Financial issued a Buy rating. The stock is approaching its ex-dividend date, which may cause a short-term price adjustment, but the overall sentiment remains cautiously optimistic.
The Fibonacci levels suggest that the stock is currently testing a critical support level. The pivot point is at $14.93, with resistance levels at $16.25 and $17.06. The stock is currently trading near the lower end of its Fibonacci range, which may indicate a potential bounce.
Based on the oversold RSI, mixed analyst sentiment, and proximity to key Fibonacci support levels, the stock is likely to experience a short-term rebound. The target price for the next trading week is $15.50, and the recommendation is to buy at current levels with a stop-loss below $13.50.
The price of CC is predicted to go up -48.37%, based on the high correlation periods with CAL. The similarity of these two price pattern on the periods is 98.74%.
CC
CAL
Barclays
2025-02-24
Price Target
$23 → $19
Upside
+17.61%
Mizuho
2025-01-07
Price Target
$22 → $21
Upside
+11.88%
Barclays
2024-11-05
Price Target
$21 → $23
Upside
+14.37%